Novo Nordisk Shares Face Challenges as Competitor Eli Lilly Enters the $1 Trillion Market Valuation Club
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Source: TipRanks
Eli Lilly's Market Achievement: Eli Lilly reached a market capitalization of $1 trillion, joining a select group of non-tech companies, while Novo Nordisk's shares have dropped nearly 44% this year, leading to a recalibration of its operations.
Leadership Changes at Novo Nordisk: Lars Rebien Sørensen has been appointed as the new board chair, aiming to support CEO Mike Doustdar's transformation plans after the ousting of the previous leader due to declining shares.
Job Cuts and Market Competition: Novo Nordisk is reducing its workforce in both the U.S. and Denmark as it faces slower sales growth and competition from Eli Lilly's successful weight-loss drug Zepbound.
Analyst Ratings and Future Outlook: Analysts maintain a Moderate Buy consensus on Novo Nordisk, with an average price target suggesting a potential 20% upside, despite recent challenges and a failed acquisition of the startup Metsera.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.960
Low
24.00
Averages
28.56
High
35.00
Current: 26.960
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IP Group PLC Reports 13% NAV Growth and Share Buyback Program
- NAV Growth: IP Group PLC (IPZYF) reported a 13% increase in NAV per share to 110p, driven by significant advancements in obesity drug compounds developed by Pfizer, which lays a solid foundation for future investments.
- Cash Flow and Buybacks: The company generated £68 million in cash exits, facilitating high-conviction investment opportunities and a buyback program that retired nearly 10% of shares, thereby enhancing shareholder confidence and improving capital structure.
- Portfolio Performance: Portfolio companies raised over £900 million in third-party capital, indicating strong external validation despite market challenges, attracting high-caliber global investors.
- Market Risks and Challenges: Despite positive financial performance, the company faces uncertainty regarding the clinical and regulatory progress of Pfizer's obesity drug, with only a 47% chance of success, while the capital intensity and high interest rates pose challenges for early-stage hydrogen businesses.
See More
PFIZER: LB6V VACCINE CANDIDATE SHOWS GOOD TOLERABILITY WITH NO SAFETY ISSUES FOUND DURING ANALYSIS
- Vaccine Candidate Tolerance: The Pfizer vaccine candidate was well tolerated by participants in clinical trials.
- Safety Concerns: No safety concerns were identified during the analysis of the vaccine candidate.
See More
PFIZER: INTENDS TO SUBMIT LB6V VACCINE CANDIDATE TO REGULATORS
- Pfizer's Vaccine Submission: Pfizer is preparing to submit applications for regulatory approval of its LB6V vaccine candidate.
- Regulatory Authorities Involvement: The submission will be directed to relevant regulatory authorities for evaluation and potential authorization.
See More
PFIZER: LB6V VACCINE CANDIDATE DEMONSTRATES OVER 70% EFFICACY IN LYME DISEASE PREVENTION FOR INDIVIDUALS AGED FIVE AND OLDER
- Vaccine Efficacy: Pfizer's vaccine candidate demonstrated over 70% efficacy in preventing Lyme disease.
- Target Population: The study focused on individuals aged five years and older.
See More
PFIZER: GUGGENHEIM INCREASES TARGET PRICE TO $36, UP FROM $35
- Price Increase Announcement: Pfizer has raised the target price for its stock from $35 to $36.
- Market Impact: This adjustment reflects the company's confidence in its financial performance and future prospects.
See More
Pfizer Stock Shows Signs of Recovery, Attracting Investor Interest
- Stock Performance Recovery: Pfizer's stock has risen 8% over the past year, showing relative resilience compared to its 25% decline over the last five years and the S&P 500's 4% drop, making it appealing to safety-seeking investors.
- High Dividend Appeal: With a dividend yield of 6.4%, Pfizer has become a favored high-yield stock amid increasing market uncertainty, providing stable cash flow as economic turmoil and rising commodity prices persist.
- Valuation Opportunity: Pfizer's forward price-to-earnings ratio is just over 9, indicating severe undervaluation; despite uncertainties regarding future growth, its stable business model and high dividend offer a margin of safety that may attract long-term investors.
- Revenue Stability: Pfizer reported revenue of $62.6 billion, a 2% operational decline year-over-year, which, while not ideal, demonstrates resilience in the current economic climate, and combined with its acquisition strategy, may present growth opportunities that enhance its investment appeal.
See More
IP Group PLC Reports 13% NAV Growth and Share Buyback Program
- NAV Growth: IP Group PLC (IPZYF) reported a 13% increase in NAV per share to 110p, driven by significant advancements in obesity drug compounds developed by Pfizer, which lays a solid foundation for future investments.
- Cash Flow and Buybacks: The company generated £68 million in cash exits, facilitating high-conviction investment opportunities and a buyback program that retired nearly 10% of shares, thereby enhancing shareholder confidence and improving capital structure.
- Portfolio Performance: Portfolio companies raised over £900 million in third-party capital, indicating strong external validation despite market challenges, attracting high-caliber global investors.
- Market Risks and Challenges: Despite positive financial performance, the company faces uncertainty regarding the clinical and regulatory progress of Pfizer's obesity drug, with only a 47% chance of success, while the capital intensity and high interest rates pose challenges for early-stage hydrogen businesses.
See More
PFIZER: LB6V VACCINE CANDIDATE SHOWS GOOD TOLERABILITY WITH NO SAFETY ISSUES FOUND DURING ANALYSIS
- Vaccine Candidate Tolerance: The Pfizer vaccine candidate was well tolerated by participants in clinical trials.
- Safety Concerns: No safety concerns were identified during the analysis of the vaccine candidate.
See More
PFIZER: INTENDS TO SUBMIT LB6V VACCINE CANDIDATE TO REGULATORS
- Pfizer's Vaccine Submission: Pfizer is preparing to submit applications for regulatory approval of its LB6V vaccine candidate.
- Regulatory Authorities Involvement: The submission will be directed to relevant regulatory authorities for evaluation and potential authorization.
See More
PFIZER: LB6V VACCINE CANDIDATE DEMONSTRATES OVER 70% EFFICACY IN LYME DISEASE PREVENTION FOR INDIVIDUALS AGED FIVE AND OLDER
- Vaccine Efficacy: Pfizer's vaccine candidate demonstrated over 70% efficacy in preventing Lyme disease.
- Target Population: The study focused on individuals aged five years and older.
See More
PFIZER: GUGGENHEIM INCREASES TARGET PRICE TO $36, UP FROM $35
- Price Increase Announcement: Pfizer has raised the target price for its stock from $35 to $36.
- Market Impact: This adjustment reflects the company's confidence in its financial performance and future prospects.
See More
Pfizer Stock Shows Signs of Recovery, Attracting Investor Interest
- Stock Performance Recovery: Pfizer's stock has risen 8% over the past year, showing relative resilience compared to its 25% decline over the last five years and the S&P 500's 4% drop, making it appealing to safety-seeking investors.
- High Dividend Appeal: With a dividend yield of 6.4%, Pfizer has become a favored high-yield stock amid increasing market uncertainty, providing stable cash flow as economic turmoil and rising commodity prices persist.
- Valuation Opportunity: Pfizer's forward price-to-earnings ratio is just over 9, indicating severe undervaluation; despite uncertainties regarding future growth, its stable business model and high dividend offer a margin of safety that may attract long-term investors.
- Revenue Stability: Pfizer reported revenue of $62.6 billion, a 2% operational decline year-over-year, which, while not ideal, demonstrates resilience in the current economic climate, and combined with its acquisition strategy, may present growth opportunities that enhance its investment appeal.
See More
